Avoiding drug interactions: Here's help

Journal of Family Practice

Volumn 59, Issue 6, 2010, Pages 322-329

  Grattagliano, Ignazio ^a   Portincasa, Piero ^a   D'Ambrosio, Gaetano ^a   Palmieri, Vincenzo O ^a   Palasciano, Giuseppe ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; AZITHROMYCIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; CIMETIDINE; CLOPIDOGREL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROMYCIN; ESOMEPRAZOLE; LEVODOPA; LOSARTAN; MACROLIDE; METOCLOPRAMIDE; MEVINOLIN; NITRIC ACID DERIVATIVE; OMEPRAZOLE; PHENOBARBITAL; PHOSPHODIESTERASE V INHIBITOR; RAMIPRIL; REPAGLINIDE; SIMVASTATIN; TERFENADINE; THEOPHYLLINE; THIAZIDE DIURETIC AGENT;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOLISM; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY FAT DISTRIBUTION; CASE REPORT; COMPUTER PROGRAM; DEHYDRATION; DRUG DOSE REGIMEN; DRUG INTERACTION; DRUG METABOLISM; ELECTRONIC PRESCRIBING; FATTY LIVER; HEART ATRIUM FIBRILLATION; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOTHYROIDISM; INFECTION; INTESTINE TRANSIT TIME; KIDNEY DYSFUNCTION; LABORATORY TEST; LIVER DYSFUNCTION; LIVER METABOLISM; MALE; OBESITY; PAIN; PATIENT CARE; PHARMACOGENETICS; POLYPHARMACY; PRESCRIPTION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SEX; SIDE EFFECT; THIGH; URINALYSIS; WEAKNESS;

AGE FACTORS; CONTINUITY OF PATIENT CARE; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG PRESCRIPTIONS; HUMANS; MALE; MEDICAL HISTORY TAKING; MIDDLE AGED; PHARMACOKINETICS; POLYPHARMACY; RISK FACTORS; SOFTWARE;

EID: 77953749897     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Becker ML, Kallewaard M, Caspers PW, et al. Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf. 2007;16:641-651. (Pubitemid 47039530)
2. Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003;289:1652-1658. (Pubitemid 37430270)
3. Tulner LR, Frankfort SV, Gijsen GJ, et al. Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance. Drugs Aging. 2008;25:343-355.
4. Cadieux RJ. Drug interactions in the elderly. How multiple drag use increases risk exponentially. Postgrad Med. 1989;86:179-186.
5. Shapiro LE, Shear NH. Drug interactions: proteins, pumps, and P-450S. J Am Acad Dermatol. 2002;47:467-484.
6. Sitar DS. Aging issues in drug disposition and efficacy. Proc West Pharmacol Soc. 2007;50:16-20.
7. El Desoky ES, Derendorf H, Klotz U. Variability in response to cardiovascular drugs. Curr Clin Pharmacol. 2006;1:35-46.
8. Aparasu R, Baer R, Aparasu A. Clinically important potential drug-drug interactions in outpatient settings. Res Social Adm Pharm. 2007;3:426-437.
9. Becker ML, Kallewaard M, Caspers PW, et al. Potential determinants of drug-drug interaction associated dispensing in community pharmacies. Drug Saf. 2005;28:371-378. (Pubitemid 40733724)
10. Johnson TN, Thomson M. Intestinal metabolism and transport of drugs in children: the effects of age and disease. J Pediatr Gastroenterol Nutr. 2008;47:3-10.
11. Buurma H, Bouvy ML, De Smet PA, et al. Prevalence and determinants of pharmacy shopping behaviour. J Clin Pharm Ther. 2008;33:17-23.
12. Russmann S, Barguil Y, Cabalion P, et al. Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia. Eur J Gastroenterol Hepatol. 2003;5:1033-1036. (Pubitemid 37094305)
13. Stickel F, Patsenker E, Schuppan D. Herbal hepatotoxicity. J Hepatol. 2005;43:901-910.
14. Institute for Safe Medication Practices. ISMP medication safety alert! Available at: http://www.ismp.org/Newsletters/consumer/alerts/BrownBag.asp. Accessed May 5, 2010.
15. National Institute on Aging. Obtaining the medical history. Available at: http://www.nia.nih.gov/Healthinformation/Publications/ClinicianHB/03-history. htm. Accessed May 5, 2010.
16. Glassman PA, Simon B, Belperio P, et al. Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med Care. 2002;40:1161-1171.
17. Goldberg RM, Mabee J, Chan L, et al. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med. 1996;14:447-450. (Pubitemid 26272242)
18. Lapane KL, Waring ME, Schneider KL, et al. A mixed method study of the merits of e-prescribing drug alerts in primary care. J Gen Intern Med. 2008;23:442-446.
19. Magnus D, Rodgers S, Avery AJ. GPs' views on computerized drug interaction alerts: questionnaire survey. J Clin Pharm Ther. 2002;27:377-382. (Pubitemid 35286237)
20. Shukla UA, Pittman KA, Barbhaiya RH. Pharmacokinetic interactions of cefprozil with food, propantheline, metoclopramide, and probenecid in healthy volunteers. J Clin Pharmacol. 1992;32:725-731.
21. Levy RH, Collins C. Risk and predictability of drug interactions in the elderly. Int Rev Neurobiol. 2007;81:235-251.
22. Pauwels O. Factors contributing to carbamazepine-macrolide interactions. Pharmacol Res. 2002;45:291-298.
23. Beaird SL. HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles. J Am Pharm Assoc (Wash). 2000;40:637-644.
24. Snaith A, Pugh L, Simpson CR, et al. The potential for interaction between warfarin and coprescribed medication: a retrospective study in primary care. Am J Cardiovasc Drugs. 2008;8:207-212. (Pubitemid 351812273)
25. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009;180:713-718.
26. O'Donoghue ML, Braunwald E, Amman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374:989-997.
27. US Food and Drug Administration. Serious muscle injury with simvastatin/amiodarone combination. November 2008. Available at: http://www.accessdata.fda.gov/psn/printer.cfm?id=886. Accessed May 5, 2010.
28. US Food and Drug Administration. FDA drug safety communication: ongoing safety review of high-dose Zocor (simvastatin) and increased risk of muscle injury. March 19, 2010. Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm204882.htm. Accessed May 5, 2010.